Patents by Inventor Wei-Li Liao

Wei-Li Liao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170168057
    Abstract: Methods are provided for quantifying the ENT1, ERCC1, FOLR1, RRM1, TUBB3, TOPO1, and/or TOPO2A proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM)/Multiple Reaction Monitoring (MRM) mass spectrometry. The biological samples are treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks. A protein digest is prepared from a biological sample and the ENT1, ERCC1, FOLR1, RRM1, TUBB3, TOPO1, and/or TOPO2A proteins are quantitated in the digest by quantitating in the protein sample one or more of the peptides described by the method of SRM/MRM mass spectrometry.
    Type: Application
    Filed: July 1, 2015
    Publication date: June 15, 2017
    Inventors: David B. KRIZMAN, Todd HEMBROUGH, Sheeno THYPARAMBIL, Wei-Li LIAO, Eunkyung An
  • Publication number: 20170168055
    Abstract: Methods are provided for quantifying specific proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and can be tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A designated protein is quantitated in the sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. The proteins that can be detected and/or quantitated are TLE3, XRCC1, E-cadherin, PTEN, Vimentin, HGF, MRP1, RFC1, SYP, IDO1, and DHFR.
    Type: Application
    Filed: December 12, 2016
    Publication date: June 15, 2017
    Inventors: David Krizman, Todd Hembrough, Wei-Li Liao, Eunkyung An, Sheeno Thyparambil, Adele Blackler
  • Publication number: 20170122946
    Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the GTPase KRas Protein (KRas) that are particularly advantageous for quantifying the KRas protein directly in biological samples that have been fixed in formalin by the mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry.
    Type: Application
    Filed: January 11, 2017
    Publication date: May 4, 2017
    Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
  • Publication number: 20170122953
    Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the Serine/Threoninc-Protein Kinase B-raf (BRAF) that are particularly advantageous for quantifying the BRAF protein directly in bio-logical samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Application
    Filed: January 11, 2017
    Publication date: May 4, 2017
    Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
  • Publication number: 20170097354
    Abstract: Methods are provided for treating a gastric cancer patient. A specific Met fragment peptide is precisely quantitated by SRM-mass spectrometry directly in gastric tumor cells collected from gastric tumor tissue that was obtained from the cancer patient and compared to a reference level. If the Met peptide is below the reference level a second therapeutic regimen is used to treat the patient whereas if the Met peptide is above the reference level then a first therapeutic regimen combining, for example, the second regimen with one or more Met inhibitor therapeutic agents may be used to treat the patient.
    Type: Application
    Filed: September 26, 2016
    Publication date: April 6, 2017
    Inventors: Daniel CATENACCI, Todd HEMBROUGH, Fabiola CECCHI, Wei-Li LIAO
  • Publication number: 20170052196
    Abstract: Peptides from the tyrosine-protein kinase receptor UFO protein (AXL) are provided that are particularly advantageous for quantifying the AXL protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM)/Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and include formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks. A protein digest is prepared from the biological sample and the AXL protein is quantitated in the Liquid Tissue sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described.
    Type: Application
    Filed: April 30, 2015
    Publication date: February 23, 2017
    Applicant: Expression Pathlogy, Inc.
    Inventors: David KRIZMAN, Todd HEMBROUGH, Adele BLACKLER, Wei-Li LIAO
  • Patent number: 9558841
    Abstract: A circuit includes a fuse cell, a sense circuit and an output control circuit. The fuse cell includes an electrical fuse. The sense circuit is electrically coupled to the fuse cell and configured for generating a sense signal indicative of a programmed condition of the electrical fuse, at an output of the sense circuit. The output control circuit is electrically coupled to the output of the sense circuit, and the output control circuit is configured for latching the sense signal indicative of the electrical fuse having been programmed, during a read operation of the fuse cell.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: January 31, 2017
    Assignee: TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD.
    Inventors: Sung-Chieh Lin, Kuo-Yuan Hsu, Wei-Li Liao, Chen-Ming Hung, Yun-Han Chen, Shao-Cheng Wang
  • Patent number: 9551719
    Abstract: Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: January 24, 2017
    Assignee: EXPRESSION PATHOLOGY, INC.
    Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
  • Publication number: 20160377633
    Abstract: Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Inventors: David KRIZMAN, Todd HEMBROUGH, Sheeno THYPARAMBIL, Wei-Li LIAO
  • Publication number: 20160320398
    Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Application
    Filed: July 22, 2016
    Publication date: November 3, 2016
    Inventors: David B. KRIZMAN, Wei-Li LIAO, Sheeno THYPARAMBIL, Todd HEMBROUGH
  • Publication number: 20160313343
    Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the PD-L1 protein that are particularly advantageous for quantifying the PD-L1 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and/or paraffin embedded. PD-L1 peptides having modified or unmodified residues can be quantitated.
    Type: Application
    Filed: July 6, 2016
    Publication date: October 27, 2016
    Inventors: David B. KRIZMAN, Todd HEMBROUGH, Sheeno THYPARAMBIL, Wei-Li LIAO, Eunkyung An
  • Publication number: 20160313344
    Abstract: Specific peptides, and derived ionization characteristics of those peptides from Death Receptor 5 (DRS) protein are provided that are particularly advantageous for quantifying the DRS protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Application
    Filed: July 15, 2016
    Publication date: October 27, 2016
    Inventors: David KRIZMAN, Todd HEMBROUGH, Sheeno THYPARAMBIL, Wei-Li LIAO
  • Patent number: 9470696
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Receptor Tyrosine-Protein Kinase erbB-4 Protein (HER4) protein are provided that are particularly advantageous for quantifying the HER4 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: October 18, 2016
    Assignee: EXPRESSSION PATHOLOGY, INC.
    Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
  • Patent number: 9470687
    Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: October 18, 2016
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
  • Publication number: 20160274124
    Abstract: The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (ER), progesterone receptor (PR), and/or antigen Ki67 (Ki67) proteins that are particularly advantageous for quantifying the ER, PR, and/or Ki67 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Application
    Filed: June 6, 2016
    Publication date: September 22, 2016
    Inventors: David B. KRIZMAN, Todd HEMBROUGH, Sheeno THYPARAMBIL, Wei-Li LIAO
  • Patent number: 9442119
    Abstract: Specific peptides, and derived ionization characteristics of those peptides from Death Receptor 5 (DR5) protein are provided that are particularly advantageous for quantifying the DR5 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: September 13, 2016
    Assignee: EXPRESSION PATHOLOGY, INC.
    Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
  • Publication number: 20160216268
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Fatty acid synthase (FASN) protein are provided that are particularly advantageous for quantifying the FASN protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Application
    Filed: April 11, 2016
    Publication date: July 28, 2016
    Inventors: David B. KRIZMAN, Todd HEMBROUGH, Sheeno THYPARAMBIL, Wei-Li LIAO
  • Patent number: 9360487
    Abstract: The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (ER), progesterone receptor (PR), and/or antigen Ki67 (Ki67) proteins that are particularly advantageous for quantifying the ER, PR, and/or Ki67 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: June 7, 2016
    Assignee: EXPRESSION PATHOLOGY, INC.
    Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
  • Publication number: 20160131665
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Insulin Receptor protein (IR), and its isoforms IR-A and IR-B, that are particularly advantageous for quantifying the IR protein, IR-A isoform and/or IR-B isoform, directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Application
    Filed: January 15, 2016
    Publication date: May 12, 2016
    Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
  • Patent number: 9309554
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Fatty acid synthase (FASN) protein are provided that are particularly advantageous for quantifying the FASN protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: April 12, 2016
    Assignee: EXPRESSION PATHOLOGY, INC.
    Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao